Arrowstreet Capital Limited Partnership Sells 419,019 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Arrowstreet Capital Limited Partnership reduced its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,216,373 shares of the company’s stock after selling 419,019 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Takeda Pharmaceutical were worth $55,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical during the 4th quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the third quarter valued at approximately $40,000. BNP Paribas Financial Markets lifted its holdings in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after buying an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after acquiring an additional 1,976 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical during the third quarter valued at $52,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $14.91 on Wednesday. The firm’s fifty day moving average is $14.23 and its two-hundred day moving average is $13.92. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.31. The company has a market cap of $47.43 billion, a P/E ratio of 37.26, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.